Concepedia

Jeffrey D. Neidhart

JD

Statistics

Publications

8

Citations

1.9K

H-Index

8

Active since

1991

Affiliations

San Juan Oncology Associates(Current)

King's College Hospital

Ludwig-Maximilians-Universität München

Elmhurst Hospital Center

Cancer Research UK

Jeffrey D. Neidhart is an author at San Juan Oncology Associates specializing in oncology, chemotherapy, and cancer pharmacology.

Publications per year

1991–2020

8

Publications

8

Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia

Carlos Salama, Jian Han, Linda Yau et al. · New England Journal of Medicine · 2020 · 1.3K citations · Full text

Veterinary Medicine, Infectious Diseases, Pharmacotherapy +15

First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies

Glen J. Weiss, Joseph Chao, Jeffrey D. Neidhart et al. · Investigational New Drugs · 2013 · 220 citations · Full text

Pharmacy, Oncology, Pharmacology +14

Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial

Judith Trotman, Sally F. Barrington, David Belada et al. · The Lancet Oncology · 2018 · 159 citations · Full text

Medicine, Immunology, Oncology +13

Randomized Trial of Doxorubicin, Bisantrene, and Miltoxantrone in Advanced Breast Cancer: A Southwest Oncology Group Study

John D. Cowan, Jeffrey D. Neidhart, Suzanne McClure et al. · JNCI Journal of the National Cancer Institute · 1991 · 77 citations

Medicine, Oncology, Pharmacology +9

A randomized Phase II trial of the tumor vascular disrupting agent CA4P (fosbretabulin tromethamine) with carboplatin, paclitaxel, and bevacizumab in advanced nonsquamous non-small-cell lung cancer

Edward B. Garon, Jeffrey D. Neidhart, Nashar Y Gabrail et al. · OncoTargets and Therapy · 2016 · 58 citations · Full text

Medicine, Oncology, Pharmacology +13

1–5 of 8